| HOME >> MEDICINE >> TECHNOLOGY |
2012July 2,
2011June 30,
2012July 2,
2011Diluted net income per share on a GAAP basis$
.35$
.36$
.78$
.63Share-based compensation expense:- Cost of product sales0.010.010.010.01- Selling, general and administrative0.060.040.110.08- Research and development0.030.020.050.03Amortization of purchased intangibles- Cost of product sales0.030.030.070.06- Selling, general and administrative0.01-0.020.01- Research and development----Levitronix Medical FMV inventory adjustments--0.01-Levitronix Medical transaction costs-0.02-0.02Income tax effect of non-GAAP adjustments(0.04)(0.04)(0.09)(0.07)Diluted net income per share on a non-GAAP basis$
.45$
.44$
.96$
.77 Three Months Ended Six Months Ended June 30,
2012July 2,
2011June 30,
2012July 2,
2011Shares used to compute diluted net income per share reconciliationShares used in calculation of diluted net income per share -- GAAP59,51863,21359,51364,590Weighted average unvested restricted stock awards (1)-9125130Shares used in calculation of diluted net income per share -- non-GAAP59,51863,30459,53864,720(1)
The company adopted the two-class method in calculating net income per share on a GAAP basis, which excludes the weighted average unvested restricted stock awards outstanding
'/>"/>
| SOURCE Thoratec Corporation Copyright©2012 PR Newswire. All rights reserved |